Yestar Healthcare Holdings Co., Ltd., a leading distributor and service provider for in vitro diagnostic (IVD) reagents and products in China, has released its interim report for 2024. The report indicates a 13.5% year-on-year (YOY) decrease in the company’s overall revenue for the first half of the year, amounting to RMB 1273.8 million. The gross profit also saw a significant decline, dropping by 28.5% YOY to RMB 217.6 million.
The decline in revenue and profit has been attributed to the impact of volume-based procurement policies. The medical business segment, which contributes 91.3% to the total revenue, recorded a 12.8% YOY decrease, reaching RMB 116.24 million. Within this segment, the gross profit margin for IVD consumables experienced a notable drop of 4.4 percentage points, settling at approximately 18.1%.
As the agent for Swiss diagnostics giant Roche Diagnostics in China, Yestar manufactures medical films for Fujifilm, which are used in X-ray, MRI, and CT scanning, and also engages in the manufacturing, marketing, and sales of dental film and medical dry film products under its own brand. By the end of the reporting period, the group had a total of 134 registration/filing certificates for IVD products. The company is expected to expand its presence in emerging fields such as POCT (point-of-care testing) and gene sequencing. – Flcube.com
